4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
← catalyst calendarSponsored by Ardelyx (industry) · ARDX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
72actual
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-24 | actual | When the study began enrolling |
| Primary completion | 2026-07-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-07 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
- Drug: Tenapanor — also filed as IBSRELA
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAverage weekly SBM (week 4)
measured 4 weeks
Permalink · ARDX's whole pipeline · Catalyst calendar · Every registered study · What changed